Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).

Voriconazole may increase risk for squamous cell carcinoma in allogeneic HCT patients

09 Oct 2017

Use of voriconazole appears to increase the risk specifically for squamous cell carcinoma (SCC) in the allogeneic haematopoietic cell transplantation (HCT) population, according to a recent study.

To examine the effect of voriconazole on the risk for nonmelanoma skin cancer (NMSC), including SCC and basal cell carcinoma, researchers conducted a retrospective cohort study involving 1,220 individuals who had undergone allogeneic HCT and 1,418 who had undergone autologous HCT. Voriconazole exposure and other known risk factors for NMSC were included in multivariate analysis.

Multivariate analyses revealed that using voriconazole elevated the risk for NMSC (hazard ratio [HR], 1.82; 95 percent CI, 1.13 to 2.91) among patients who had undergone allogeneic HCT, particularly for SCC (HR, 2.25; 1.30 to 3.89). In patients who had undergone autologous HCT, using voriconazole did not contribute to an increased risk for NMSC.

In an earlier study, Wojenski and colleagues identified cumulative days of voriconazole use as a predictor of SCC development following allogeneic HCT. This information, according to them, may help guide appropriate antifungal use in this patient population. [Transpl Infect Dis 2015;17:250-8]

Meanwhile, a study by Boast and colleagues on voriconazole dosing and therapeutic drug monitoring (TDM) in children found a significant intra- and interindividual variability in voriconazole concentrations in children, particularly those <6 years of age, which warranted repeated TDM throughout treatment. The authors also recommended standardized guidelines for TDM and dose adjustment in children. [J Antimicrob Chemother 2016;71:2031-6]

The current study is limited by its retrospective design, according to researchers, adding that voriconazole has previously been tied to an increased risk for cutaneous SCC in solid organ transplant recipients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).